Dear Editor,
Naїve T-helper cells (Th0) can respond to novel pathogens that the immune system has never encountered before, as is the specific case of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the positive-sense single-stranded RNA virus responsible for the ongoing pandemic named coronavirus disease 2019 (COVID-19). Depending on the infectious agent, Th0 polarize the immune response into T-helper type 1 (Th1), the default response in immunocompetent subjects to intracellular or phagocytosable pathogens (e.g. viruses, bacteria, protozoa, fungi) and mediated by macrophages and T-cytotoxic (Tc) cells (cell-mediated immunity), or into T-helper type 2 (Th2), classically directed against extracellular non-phagocytosable pathogens, for instance helminths, and whose main effectors are eosinophils, basophils and mastocytes, as well as B cells (humoral immunity) [1]. Eosinophils play a direct role in fighting RNA viruses, as demonstrated by the presence of RNases inside their granules [1]; however, they have been negatively associated with the pathophysiology of the respiratory virus infections, since they trigger bronchoconstriction and dyspnea, besides virus-induced exacerbations of allergic airways diseases, by releasing a large amount of cationic proteins and cytokines, among which interleukin-6 (IL-6), a key mediator also for the development of the “cytokine storm” in COVID-19 fatal cases [2, 3]. At some extent, the smooth muscle cells in the tunica media of blood vessels can produce IL-6, too [4]. It belongs to Th2 cytokines class together with IL-4, IL-5, IL-9, IL-10, IL-13 and IL-25; contrariwise, IL-2, IL-12, interferon-γ and tumor necrosis factor-α are the main Th1 cytokines, able to stimulate the inducible form of the nitric oxide (NO) synthase to produce NO free radicals endowed with virucidal activity [1]. To minimize the contagion risk in healthcare personnel, we have prepared and examined a limited number of 15 peripheral blood smears from a wider series of hospitalized COVID-19 patients, just admitted to intensive care and monitored through blood tests; in all the cases, we have found cytological signals of Th2 immune response, represented by eosinophilia plus basophilia, degranulated eosinophils, Türk cells or plasma cells, together with rouleaux and Tc lymphopenia (Fig. 1). On the basis of our findings, for reasons still unclear, maybe related to the viral load, Th1 and Tc breakdown, antigenic cross-reactivity or the type of antigen-presenting cell stimulating Th0, the immune system mounts a Th2 response against SARS-CoV-2 in patients requiring intensive care, rather than a Th1 response, which would keep the infection under control by means of macrophages and Tc cells. This event is more likely in patients affected by cancer, immunodeficiency, autoimmune disorders, congestive heart failure, chronic obstructive pulmonary disease and hepatic cirrhosis, or in those who have suffered major surgery and traumatic injury, or who are on glucocorticoid therapy and total parenteral nutrition, all known conditions suppressive to Th1 immunity [1]. The mounting of a Th2 immune response allows to explain well the concurrent gastrointestinal symptoms present up to 30% of COVID-19 patients and significantly associated with dyspnea [5]; in fact, hyperperistalsis and gastric fluid acidification are also two notorious default mechanisms of defense to expel parasites governed by Th2 cytokines [1].
Fig. 1.
Cytological signals of Th2 immune response on peripheral blood smears from COVID-19 patients requiring intensive care: a on the right side of the panel, three eosinophils in a row accompanied by a basophile in the upper left corner (× 40 objective); b an eosinophil in the degranulation phase (× 100 objective); c a bilobed degranulated eosinophil in the center of the panel (× 100 objective); d an immature plasma cell (Türk cell) in the midst of prominent rouleaux (× 100 objective) (May-Grünwald stain)
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures followed were in accordance with the ethical standards and with the Helsinki Declaration of 1975, as revised in 2008.
Informed consent
Not applicable since the manuscript does not contain any patient data.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Spellberg B, Edwards JE., Jr Type 1 / type 2 immunity in infectious diseases. Clin Infect Dis. 2001;32(1):76–102. doi: 10.1086/317537. [DOI] [PubMed] [Google Scholar]
- 2.Rosenberg HF, Dyer KD, Domachowske JB. Eosinophils and their interactions with respiratory virus pathogens. Immunol Res. 2009;43(1–3):128–137. doi: 10.1007/s12026-008-8058-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (2020) The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents:105954. 10.1016/j.ijantimicag.2020.105954 [DOI] [PMC free article] [PubMed]
- 4.Song Y, Shen H, Schenten D, Shan P, Lee PJ, Goldstein DR. Aging enhances the basal production of IL-6 and CCL2 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2012;32(1):103–109. doi: 10.1161/ATVBAHA.111.236349. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Wei XS, Wang X, Niu YR, Ye LL, Peng WB, Wang ZH, Yang WB, Yang BH, Zhang JC, Ma WL, Wang XR, Zhou Q (2020) Clinical characteristics of SARS-CoV-2 infected pneumonia with diarrhea. Lancet Respir Med SSRN. 10.2139/ssrn.3546120